Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01693718 · ClinicalTrials.gov registry record · Phase 2

A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer

A Phase 2 study, sponsored by University of Chicago.

Completed
Registry status
Phase 2
Development phase
44
Enrollment target

NCT01693718: Completed Phase 2 study, sponsored by University of Chicago.

NCT01693718 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01693718, a Phase 2 study, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
Phase 2
Development phase
44 participants
Enrollment target

Study Summary

The goal of the study is to test a particular combination of drugs and determine their ability to completely eliminate head and neck cancer.

Primary Outcome

To evaluate the activity of 5 cycles of C-FHX/G-CSF in previously untreated patients with stage II and IV locoregionally advanced head and neck cancer.

Interventions

  • DRUG Cisplatin
  • DRUG Hydroxyurea
  • DRUG 5- Fluorouracil

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2003-03
Est. Completion 2004-09
Phase Phase 2
University of Chicago

796 total trials

What the finished NCT01693718 record still lists

NCT01693718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.

NCT01693718 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01693718 about?

NCT01693718 is a clinical study titled "A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer". The goal of the study is to test a particular combination of drugs and determine their ability to completely eliminate head and neck cancer.

What is the current status of trial NCT01693718?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2003-03. Estimated completion is 2004-09.

What interventions are being tested in trial NCT01693718?

The interventions under investigation include: Cisplatin (DRUG), Hydroxyurea (DRUG), 5- Fluorouracil (DRUG).

Who is sponsoring clinical trial NCT01693718?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01693718's enrollment target sits among peer trials

44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01693718, the US trial registry maintained by the National Library of Medicine. NCT01693718 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.